Despite improvements in
cardiovascular disease (CVD) outcomes by
cholesterol-lowering
statin therapy, the high rate of CVD is still a great concern worldwide.
Dehydrocorydaline (DHC) is an alkaloidal compound isolated from the traditional Chinese herb Corydalis yanhusuo. Emerging evidence shows that DHC has anti-inflammatory and antithrombotic benefits, but whether DHC exerts any antiatherosclerotic effects remains unclear. Our study revealed that intraperitoneal (i.p.) injection of DHC in
apolipoprotein E-deficient (
ApoE-/-) mice not only inhibited
atherosclerosis development but also improved aortic compliance and increased plaque stability. In addition, DHC attenuated systemic and vascular
inflammation in
ApoE-/- mice. As macrophage
inflammation plays an essential role in the pathogenesis of
atherosclerosis, we next examined the direct effects of DHC on bone marrow-derived macrophages (BMDMs) in vitro. Our
RNA-seq data revealed that DHC dramatically decreased the levels of proinflammatory gene clusters. We verified that DHC significantly downregulated proinflammatory
interleukin (IL)-1β and
IL-18 mRNA levels in a time- and concentration-dependent manner. Furthermore, DHC decreased
lipopolysaccharide (LPS)-induced
inflammation in BMDMs, as evidenced by the reduced
protein levels of CD80, iNOS, NLRP3, IL-1β, and
IL-18. Importantly, DHC attenuated LPS-induced activation of p65 and the
extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. Thus, we conclude that DHC ameliorates
atherosclerosis in
ApoE-/- mice by inhibiting
inflammation, likely by targeting macrophage p65- and ERK1/2-mediated pathways.